Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682381 · ClinicalTrials.gov registry record · Phase 3
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT02682381 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 59 participants.
The verdict
NCT02682381, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose of this study is to evaluate the safety and efficacy of teduglutide in children up to the age of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to receive the study drug or to participate in a standard-of-care arm. All participants who complete the study may be eligible to receive the study drug in a long-term extension study.
Interventions
- OTHER Standard of Care
- DRUG Teduglutide 0.05mg/kg
- DRUG Teduglutide 0.025 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2016-06-23 |
| Est. Completion | 2017-08-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02682381
The ClinicalTrials.gov registry entry for NCT02682381 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.
NCT02682381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02682381 about?
NCT02682381 is a clinical study titled "Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition". Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose of this study is to evaluate the safety and efficacy of teduglutide in children up to the age of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to receive the study drug or ...
What is the current status of trial NCT02682381?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2016-06-23. Estimated completion is 2017-08-18.
What interventions are being tested in trial NCT02682381?
The interventions under investigation include: Standard of Care (OTHER), Teduglutide 0.05mg/kg (DRUG), Teduglutide 0.025 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02682381?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.